Jaguar Health's Late-Breaking Abstracts Accepted at ESPGHAN Meeting

Jaguar Health, Inc. has announced the acceptance of two late-breaking abstracts at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) meeting. The abstracts focus on the use of liquid oral crofelemer for treating intestinal failure (IF) in pediatric patients. The condition, resulting from microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS), requires life-sustaining parenteral support.

Crofelemer, as adjunct therapy, has shown promise in reducing the need for parenteral support. Patients in the study experienced reduced parenteral support needs, improved growth, and enhanced quality of life. The treatment has been well tolerated, making it a hopeful option for managing this debilitating condition.

Jaguar's subsidiary Napo Pharmaceuticals aims to file a New Drug Application for this treatment by mid-2027. Meanwhile, adult trials are underway in Europe to further investigate crofelemer's efficacy for IF due to SBS.